Alnylam Pharmaceuticals authorized a stock-repurchase program of up to $1 billion, with about half the planned purchases targeted by year-end 2026 and the remainder during 2027. Separately, the company said Chief Commercialization Officer Tolga Tanguler plans to leave in December.
Key details
- Buyback authorization: Alnylam’s board approved repurchases of up to $1 billion of the company’s common stock on November 2.
- Expected pace: The company anticipates buying approximately $500 million of shares by the end of 2026, with the balance during 2027. The schedule and total amount will depend on factors including the share price, business and market conditions, liquidity needs, capital requirements and other investment opportunities.
- How shares may be bought: Purchases may take place in the open market, through privately negotiated transactions or by other means. Open-market purchases may use trading plans designed to allow transactions under preset conditions.
- No commitment to spend the full amount: The program has no expiration date and does not require Alnylam to repurchase any particular number of shares or dollar amount. It can be changed, paused or ended at any time.
- Commercial leadership change: Tanguler is expected to leave his role as executive vice president and chief commercialization officer in December 2026. Alnylam and Tanguler intend to enter into a written agreement setting out the terms of his departure by his separation date; those terms have not yet been provided.
Plain-English implications
The buyback gives Alnylam flexibility to return capital to shareholders, but the authorization is not a promise that the company will complete $1 billion in purchases. Tanguler’s planned departure marks a change in the company’s commercial leadership; details of the transition and his departure arrangements remain to be finalized.